XOMAO / XOMA Royalty Corporation - Preferred Stock - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

Table 1: Transaction Valuation

Calculation of Filing Fee Tables Table 1: Transaction Valuation Transaction Valuation Fee Rate Amount of Filing Fee Fees to be Paid 1 $ 10,522,118.

SCHEDULE A INFORMATION CONCERNING MEMBERS OF THE BOARDS OF DIRECTORS AND THE EXECUTIVE OFFICERS OF PURCHASER.

EX-99.(a)(1)(E) Exhibit 99.(a)(1)(E) SCHEDULE A INFORMATION CONCERNING MEMBERS OF THE BOARDS OF DIRECTORS AND THE EXECUTIVE OFFICERS OF PURCHASER. 1. XOMA Royalty Corporation XOMA Royalty Corporation’s primary business is as a biotech royalty aggregator with a sizable portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commer

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1) LAVA THERAPEUTICS N.V. (Name of Subject Company (Is

SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1) LAVA THERAPEUTICS N.V. (Name of Subject Company (Issuer)) XOMA ROYALTY CORPORATION (Name of Filing Persons (Offeror)) Common Shares, with a nominal value of €0.12 Per Share (Title of Class of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 HILLEVAX, INC. (Name of Subject Company (Issuer)) XRA 4 CORP. (Name o

SC TO-T UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 HILLEVAX, INC. (Name of Subject Company (Issuer)) XRA 4 CORP. (Name of Filing Persons (Co-Offeror)) XOMA ROYALTY CORPORATION (Name of Filing Persons (Co-Offeror)) Common Stock, Par Value $0.0001 Per Share (Title

Offer to Purchase All Outstanding Shares of Common Stock HILLEVAX, INC. A Delaware corporation A Price per Share of $1.95, Plus One Non-Transferable Contractual Contingent Value Right (“CVR”) for Each Share, Which Represents the Right to Receive Pote

EX-99.(a)(1)(C) Exhibit (a)(1)(C) Offer to Purchase All Outstanding Shares of Common Stock of HILLEVAX, INC. A Delaware corporation at A Price per Share of $1.95, Plus One Non-Transferable Contractual Contingent Value Right (“CVR”) for Each Share, Which Represents the Right to Receive Potential Payments, in Cash, Contingent upon Receipt of Any CVR Proceeds, as Described in the CVR Agreement Pursua

Table 1: Transaction Valuation

Calculation of Filing Fee Tables Table 1: Transaction Valuation Transaction Valuation Fee Rate Amount of Filing Fee Fees to be Paid 1 $ 105,094,400.

Offer to Purchase All Outstanding Shares of Common Stock HILLEVAX, INC. A Price per Share of $1.95, Plus One Non-Transferable Contractual Contingent Value Right (“CVR”) for Each Share, Which Represents the Right to Receive Potential Payments, in Cash

EX-99.(a)(1)(D) Exhibit (a)(1)(D) Offer to Purchase All Outstanding Shares of Common Stock of HILLEVAX, INC. At A Price per Share of $1.95, Plus One Non-Transferable Contractual Contingent Value Right (“CVR”) for Each Share, Which Represents the Right to Receive Potential Payments, in Cash, Contingent upon Receipt of Any CVR Proceeds, as Described in the CVR Agreement Pursuant to the Offer to Purc

Letter of Transmittal To Tender Direct Registered Shares of Common Stock HILLEVAX, INC. a Delaware corporation A Price per Share of $1.95, Plus One Non-Transferable Contractual Contingent Value Right (“CVR”) for Each Share, Which Represents the Right

EX-99.(a)(1)(B) Exhibit (a)(1)(B) Letter of Transmittal To Tender Direct Registered Shares of Common Stock of HILLEVAX, INC. a Delaware corporation at A Price per Share of $1.95, Plus One Non-Transferable Contractual Contingent Value Right (“CVR”) for Each Share, Which Represents the Right to Receive Potential Payments, in Cash, Contingent upon Receipt of Any CVR Proceeds, as Described in the Offe

Offer to Purchase All Outstanding Shares of Common Stock HILLEVAX, INC. A Price per Share of $1.95, Plus One Contingent Value Right (“CVR”), Which Represents the Right to Receive Potential Payments, in Cash, Contingent upon Receipt of Any CVR Proceed

EX-99.(a)(1)(A) Exhibit (a)(1)(A) Offer to Purchase All Outstanding Shares of Common Stock of HILLEVAX, INC. at A Price per Share of $1.95, Plus One Contingent Value Right (“CVR”), Which Represents the Right to Receive Potential Payments, in Cash, Contingent upon Receipt of Any CVR Proceeds, as Described in the CVR Agreement by XRA 4 CORP. and XOMA ROYALTY CORPORATION THE OFFER AND WITHDRAWAL RIGH

MUTUAL NONDISCLOSURE AGREEMENT

EX-99.(d)(2) Exhibit (d) (2) MUTUAL NONDISCLOSURE AGREEMENT This Mutual Nondisclosure Agreement (the “Agreement”), dated as of December 2, 2024 is between HilleVax, Inc., a Delaware corporation (“Company”), whose address for notices under this Agreement is 321 Harrison Ave, Suite 500, Boston, MA 02118, and XOMA (US) LLC, a Delaware limited liability company (the “Other Party”), whose address is 22

Offer to Purchase All Outstanding Common Shares LAVA THERAPEUTICS N.V. A Dutch public limited liability company A Cash Amount per Share between $1.16 and $1.24, Consisting of a Base Price Per Share of $1.16 and an Additional Price Per Share of up to

EX-99.(a)(1)(C) Exhibit (a)(1)(C) Offer to Purchase All Outstanding Common Shares of LAVA THERAPEUTICS N.V. A Dutch public limited liability company at A Cash Amount per Share between $1.16 and $1.24, Consisting of a Base Price Per Share of $1.16 and an Additional Price Per Share of up to $0.08, Plus One Non-Transferable Contractual Contingent Value Right (“CVR”) for Each Share, Which Represents t

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 11, 2025 XOMA ROYALTY CORP

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 11, 2025 XOMA ROYALTY CORPORATION (Exact Name of Registrant as Specified in Charter) Nevada 001-39801 52-2154066 (State or Other Jurisdiction of Incorporation) (Commission File

Letter of Transmittal To Tender Common Shares LAVA THERAPEUTICS N.V. a Dutch public limited liability company A Cash Amount per Share between $1.16 and $1.24, Consisting of a Base Price Per Share of $1.16 and an Additional Price Per Share of up to $0

EX-99.(a)(1)(B) Exhibit (a)(1)(B) Letter of Transmittal To Tender Common Shares of LAVA THERAPEUTICS N.V. a Dutch public limited liability company at A Cash Amount per Share between $1.16 and $1.24, Consisting of a Base Price Per Share of $1.16 and an Additional Price Per Share of up to $0.08, Plus One Non-Transferable Contractual Contingent Value Right (“CVR”) for Each Share, Which Represents the

CONTINGENT VALUE RIGHTS AGREEMENT

EX-2.2 Exhibit 2.2 CONTINGENT VALUE RIGHTS AGREEMENT This CONTINGENT VALUE RIGHTS AGREEMENT, dated as of August 11, 2025 (this “Agreement”), is entered into by and among XOMA Royalty Corporation, a Nevada corporation (the “Parent”), Broadridge Corporate Issuer Solutions, LLC, a Pennsylvania limited liability company, as Rights Agent (as defined herein), and WT Representative LLC, a Delaware limite

Table 1: Transaction Valuation

Calculation of Filing Fee Tables Table 1: Transaction Valuation Transaction Valuation Fee Rate Amount of Filing Fee Fees to be Paid 1 $ 30,514,142.

CONFIDENTIALITY AGREEMENT

EX-99.(d)(2) Exhibit (d) (2) CONFIDENTIALITY AGREEMENT THIS CONFIDENTIALITY AGREEMENT (“Agreement”) is being entered into as of June 2, 2025, between LAVA Therapeutics N.V., a company organized under the laws of the Netherlands (the “Company”), and XOMA (US) LLC, a Delaware limited liability company (“Counterparty”). In order to facilitate the consideration and negotiation of a possible negotiated

Offer to Purchase All Outstanding Common Shares LAVA THERAPEUTICS N.V. A Dutch public limited liability company A Cash Amount per Share between $1.16 and $1.24, Consisting of a Base Price Per Share of $1.16 and an Additional Price Per Share of up to

EX-99.(a)(1)(D) Exhibit (a)(1)(D) Offer to Purchase All Outstanding Common Shares of LAVA THERAPEUTICS N.V. A Dutch public limited liability company at A Cash Amount per Share between $1.16 and $1.24, Consisting of a Base Price Per Share of $1.16 and an Additional Price Per Share of up to $0.08, Plus One Non-Transferable Contractual Contingent Value Right (“CVR”) for Each Share, Which Represents t

Offer to Purchase All Outstanding Common Shares LAVA THERAPEUTICS N.V. A Dutch public limited liability company A Cash Amount per Share between $1.16 and $1.24, Consisting of a Base Price Per Share of $1.16 and an Additional Price Per Share of up to

EX-99.(a)(1)(A) Exhibit (a)(1)(A) Offer to Purchase All Outstanding Common Shares of LAVA THERAPEUTICS N.V. A Dutch public limited liability company at A Cash Amount per Share between $1.16 and $1.24, Consisting of a Base Price Per Share of $1.16 and an Additional Price Per Share of up to $0.08, Plus One Contingent Value Right (“CVR”), Which Represents the Right to Receive Potential Payments, in C

AGREEMENT AND PLAN OF MERGER XOMA ROYALTY CORPORATION XRA 3 CORP. TURNSTONE BIOLOGICS CORP. DATED AS OF JUNE 26, 2025

EX-2.1 Exhibit 2.1 STRICTLY PRIVATE AND CONFIDENTIAL EXECUTION VERSION AGREEMENT AND PLAN OF MERGER AMONG XOMA ROYALTY CORPORATION XRA 3 CORP. AND TURNSTONE BIOLOGICS CORP. DATED AS OF JUNE 26, 2025 TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 2    SECTION 1.01 Definitions 2 SECTION 1.02 Interpretation and Rules of Construction 12 ARTICLE II THE OFFER 12 SECTION 2.01 The Offer 12 SECTION 2.02 Comp

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 LAVA THERAPEUTICS N.V. (Name of Subject Company (Issuer)) XOMA ROYALT

SC TO-T UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 LAVA THERAPEUTICS N.V. (Name of Subject Company (Issuer)) XOMA ROYALTY CORPORATION (Name of Filing Persons (Offeror)) Common Shares, with a nominal value of €0.12 Per Share (Title of Class of Securities) N515171

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39801 XOM

XOMA Royalty Reports Second Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements Business development: Purchased mezagitamab royalty and milestone rights held by BioInvent International and will secure royalty e

EX-99.1 Exhibit 99.1 XOMA Royalty Reports Second Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements Business development: Purchased mezagitamab royalty and milestone rights held by BioInvent International and will secure royalty economic interests in two early-stage partnered assets through XOMA Royalty’s recently announced acquisition of LAVA Therapeutics.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2025 XOMA ROYALTY CORP

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2025 XOMA ROYALTY CORPORATION (Exact Name of Registrant as Specified in Charter) Nevada 001-39801 52-2154066 (State or Other Jurisdiction of Incorporation) (Commission File

Certificate of Designation of Series X Convertible Preferred Stock

Exhibit 3.2 XOMA ROYALTY CORPORATION CERTIFICATE OF DESIGNATION OF SERIES X CONVERTIBLE PREFERRED STOCK Pursuant to Nevada Revised Statutes 78.1955 XOMA ROYALTY CORPORATION, a Nevada corporation (the “Corporation”), in accordance with the provisions of Section 78.1955 of the Nevada Revised Statutes (as amended from time to time, the “NRS”), does hereby certify that the following resolution was dul

Certificate of Designation of 8.625% Series A Cumulative Perpetual Preferred Stock

Exhibit 3.3 XOMA ROYALTY CORPORATION CERTIFICATE OF DESIGNATION OF 8.625% SERIES A CUMULATIVE PERPETUAL PREFERRED STOCK Pursuant to Nevada Revised Statutes 78.1955 XOMA Royalty Corporation, a Nevada corporation (the “Corporation”), hereby certifies that, pursuant to the authority expressly vested in the Board of Directors of the Corporation by the Articles of Incorporation of the Corporation (as a

Certificate of Designation of 8.375% Series B Cumulative Perpetual Preferred Stock

Exhibit 3.4 XOMA ROYALTY CORPORATION CERTIFICATE OF DESIGNATION OF 8.375% SERIES B CUMULATIVE PERPETUAL PREFERRED STOCK Pursuant to Nevada Revised Statutes 78.1955 XOMA Royalty Corporation, a Nevada corporation (the “Corporation”), hereby certifies that, pursuant to the authority expressly vested in the Board of Directors of the Corporation by the Articles of Incorporation of the Corporation (as a

Form of Indemnity Agreement for Directors and Officers

Exhibit 10.2 INDEMNITY AGREEMENT This Indemnity Agreement (this “Agreement”) dated as of , is made by and between XOMA Royalty Corporation, a Nevada corporation (the “Company”), and (“Indemnitee”). Recitals A.The Company desires to attract and retain the services of highly qualified individuals as directors, officers, employees and agents. B.The Company’s bylaws (the “Bylaws”) require that the Com

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2) TURNSTONE BIOLOGICS CORP. (Name of Subject Company

SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2) TURNSTONE BIOLOGICS CORP. (Name of Subject Company (Issuer)) XOMA ROYALTY CORPORATION (Name of Filing Persons (Offeror)) Common Stock, Par Value $0.001 Per Share (Title of Class of Securities

Press Release of Purchaser issued on August 11, 2025.

EX-99.(a)(5)(B) Exhibit (a)(5)(B) XOMA Royalty Announces Closing of Tender Offer for Turnstone Biologics - Turnstone Stockholders Received $0.34 Per Share in Cash Plus Contingent Value Right - EMERYVILLE, Calif., August 11, 2025 (GLOBE NEWSWIRE) – XOMA Royalty Corporation (NASDAQ: XOMA) (“XOMA Royalty” or the “Company”), a biotechnology royalty aggregator playing a distinctive role in helping biot

Press Release issued by XOMA Royalty Corporation on August 4, 2025.

EX-99.1 Exhibit 99.1 HilleVax Enters into a Definitive Agreement to be Acquired by XOMA Royalty for $1.95 in Cash per Share Plus a Contingent Value Right BOSTON, Mass,. and EMERYVILLE, Calif., August 4, 2025 (GLOBE NEWSWIRE) – HilleVax, Inc. (“HilleVax” or “the Company”) (NASDAQ: HLVX) and XOMA Royalty Corporation (“XOMA Royalty”) (NASDAQ: XOMA) announced today they have entered into a definitive

Joint Press Release issued by XOMA Royalty Corporation and LAVA Therapeutics N.V. on August 4, 2025.

EX-99.1 Exhibit 99.1 XOMA Royalty Enters into Agreement to Acquire LAVA Therapeutics for Between $1.16 and $1.24 Per Share in Cash, Plus a Contingent Value Right -XOMA Royalty adds milestone and royalty economics associated with two partnered assets- EMERYVILLE, Calif., UTRECHT, The Netherlands, and PHILADELPHIA, Penn, August 4, 2025 (GLOBE NEWSWIRE) – XOMA Royalty Corporation (“XOMA Royalty”) (NA

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Rule 14d-100) TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 LAVA Therapeutics N.V. (Name of Subject Company (Issue

SC TO-C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Rule 14d-100) TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 LAVA Therapeutics N.V. (Name of Subject Company (Issuer)) XOMA ROYALTY CORPORATION (Name of Filing Persons (Offeror 1)) Ordinary Shares, Par Value €0.12 Per Share (Title of Class of Securities) N5

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Rule 14d-100) TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 HILLEVAX, INC. (Name of Subject Company (Issuer)) XOMA

SC TO-C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Rule 14d-100) TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 HILLEVAX, INC. (Name of Subject Company (Issuer)) XOMA ROYALTY CORPORATION (Name of Filing Persons (Offeror 1)) XRA 4 CORP. (Name of Filing Persons (Offeror 2)) Common Stock, Par Value $0.0001 Per

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1) TURNSTONE BIOLOGICS CORP. (Name of Subject Company

SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1) TURNSTONE BIOLOGICS CORP. (Name of Subject Company (Issuer)) XOMA ROYALTY CORPORATION (Name of Filing Persons (Offeror)) Common Stock, Par Value $0.001 Per Share (Title of Class of Securities

Amended and Restated Offer to Purchase, dated July 23, 2025.

EX-99.(a)(1)(E) Table of Contents Exhibit (a)(1)(E) Amended and Restated Offer to Purchase All Outstanding Shares of Common Stock of TURNSTONE BIOLOGICS CORP. at A Price per Share of $0.34, Plus One Contingent Value Right (“CVR”), Which Represents the Right to Receive Potential Payments, in Cash, Contingent upon Receipt of Any CVR Proceeds, as Described in the CVR Agreement by XOMA ROYALTY CORPORA

Offer to Purchase, dated July 11, 2025.

Table of Contents Exhibit (a)(1)(A) Offer to Purchase All Outstanding Shares of Common Stock of TURNSTONE BIOLOGICS CORP.

Confidentiality Agreement dated April 16, 2025 between Turnstone and Purchaser.

Exhibit (d)(2) CONFIDENTIALITY AGREEMENT THIS CONFIDENTIALITY AGREEMENT (“Agreement”) is being entered into as of April 16, 2025, between Turnstone Biologics Corp.

Form of Letter to Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees.

Exhibit (a)(1)(C) Offer to Purchase All Outstanding Shares of Common Stock of TURNSTONE BIOLOGICS CORP.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 TURNSTONE BIOLOGICS CORP. (Name of Subject Company (Issuer)) XOMA ROY

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 TURNSTONE BIOLOGICS CORP. (Name of Subject Company (Issuer)) XOMA ROYALTY CORPORATION (Name of Filing Persons (Offeror)) Common Stock, Par Value $0.001 Per Share (Title of Class of Securities) 98419J206 (CUSIP Number of

Form of Letter to Clients for Use by Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees.

Exhibit (a)(1)(D) Offer to Purchase All Outstanding Shares of Common Stock of TURNSTONE BIOLOGICS CORP.

Filing Fee Table.

EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables SC TO-T (Form Type) TURNSTONE BIOLOGICS CORP.

Form of Letter of Transmittal.

Exhibit (a)(1)(B) Letter of Transmittal To Tender Shares of Common Stock of TURNSTONE BIOLOGICS CORP.

Turnstone Biologics Corp. Enters into Agreement to be Acquired by XOMA Royalty Corporation for $0.34 in Cash Per Share Plus a Contingent Value Right

Exhibit 99.1 Turnstone Biologics Corp. Enters into Agreement to be Acquired by XOMA Royalty Corporation for $0.34 in Cash Per Share Plus a Contingent Value Right EMERYVILLE and SAN DIEGO, Calif., June 27, 2025 (GLOBE NEWSWIRE) – XOMA Royalty Corporation (“XOMA Royalty”) (Nasdaq: XOMA) and Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq-CM: TSBX) today announced that they have ente

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Rule 14d-100) TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 TURNSTONE BIOLOGICS CORP. (Name of Subject Company (Is

SC TO-C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Rule 14d-100) TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 TURNSTONE BIOLOGICS CORP. (Name of Subject Company (Issuer)) XOMA ROYALTY CORPORATION (Name of Filing Persons (Offeror)) Common Stock, Par Value $0.001 Per Share (Title of Class of Securities) 984

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): May 28, 2025 XOMA ROYALTY CORPORA

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): May 28, 2025 XOMA ROYALTY CORPORATION (Exact Name of Registrant as Specified in Charter) Nevada 001-39801 52-2154066 (State or Other Jurisdiction of Incorporation) (Commission File Nu

Bylaws of the Company

EX-3.2 Exhibit 3.2 BYLAWS OF XOMA ROYALTY CORPORATION (the “Company”) ARTICLE I OFFICES Section 1. The registered office shall be the street address of the Company’s registered agent. Section 2. The Company may also have offices at such other places both within and without the State of Nevada as the Board of Directors of the Company (the “Board of Directors”) may from time to time determine or the

Amended and Restated 2010 Long Term Incentive and Stock Award Plan

Exhibit 10.1 XOMA ROYALTY CORPORATION AMENDED AND RESTATED 2010 LONG TERM INCENTIVE AND STOCK AWARD PLAN 1. Purposes. The XOMA Royalty Corporation Amended and Restated 2010 Long Term Incentive and Stock Award Plan (the “Plan”) was originally adopted as the XOMA Corporation 2010 Long Term Incentive and Stock Award Plan, effective as of July 21, 2010 (the “Original Effective Date”) and was most rece

Plan of Conversion of the Company

EX-2.1 Exhibit 2.1 NEVADA PLAN OF CONVERSION This Plan of Conversion (this “Plan”) is adopted as of May 29, 2025 and sets forth certain terms of the conversion of XOMA Royalty Corporation, a Delaware corporation (the “Delaware Corporation”), to a Nevada corporation (the “Nevada Corporation”), pursuant to the terms of the General Corporation Law of the State of Delaware (as amended, the “DGCL”) and

Articles of Incorporation of the Company

Exhibit 3.1 ARTICLES OF INCORPORATION OF XOMA ROYALTY CORPORATION ARTICLE I The name of the corporation is XOMA Royalty Corporation (the “Corporation”). ARTICLE II The registered office of the Corporation shall be the street address of its registered agent in the State of Nevada. The Corporation may, from time to time, in the manner provided by law, change the registered agent and registered offic

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): May 13, 2025 XOMA ROYALTY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-39801 52-2154066 (State or Other Jurisdiction of Incorporation) (Commission File

XOMA Royalty Reports First Quarter 2025 Financial Results and Highlights Business Achievements Pipeline advancements: The Marketing Authorization Application (MAA) for Day One Biopharmaceuticals and Ipsen’s tovorafenib was accepted for review by the

Exhibit 99.1 XOMA Royalty Reports First Quarter 2025 Financial Results and Highlights Business Achievements Pipeline advancements: The Marketing Authorization Application (MAA) for Day One Biopharmaceuticals and Ipsen’s tovorafenib was accepted for review by the European Marketing Authority (EMA) and Takeda initiated its Phase 3 trial exploring mezagitamab for the treatment of chronic primary immu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39801 XO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitte

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitte

Description of Registrant’s Securities

Exhibit 4.10 DESCRIPTION OF CAPITAL STOCK The following is a description of the Common Stock, $0.0075 par value (the “Common Stock”), Preferred Stock, $0.05 par value (the “Preferred Stock”) and depositary shares of XOMA Royalty Corporation (“we,” “us,” “our” or the “Company”). The Common Stock, 8.625% Series A Cumulative Perpetual Preferred Stock, $0.05 par value (the “Series A Preferred Stock”),

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39801 XOMA RO

Amendment No. 1, dated March 4, 2024, to the Royalty Purchase Agreement dated March 22, 2021 between XOMA (US) LLC and Viracta Therapeutics, Inc.

Exhibit 10.30 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED (INDICATED BY: [***]) FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE OF INFORMATION THAT THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE OR CONFIDENTIAL AMENDMENT NO. 1 TO ROYALTY PURCHASE AGREEMENT This Amendment No. 1 to Royalty Purchase Agreement (this “Amendment”) is entered into as of March 4, 202

XOMA Royalty Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Business Achievements Doubled the royalty and milestone portfolio to over 120 royalty assets with significant milestone potential through five transactions in 202

EX-99.1 Exhibit 99.1 XOMA Royalty Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Business Achievements Doubled the royalty and milestone portfolio to over 120 royalty assets with significant milestone potential through five transactions in 2024 Completed two whole company acquisitions to unlock shareholder value Day One’s OJEMDA™ (tovorafenib) and Zevra’s MIPLYFFA™ (ari

Insider Trading Policy

Exhibit 19.1 Insider Trading Policy This Insider Trading Policy describes the standards of XOMA Royalty Corporation (the “Company”) and its subsidiaries (the "Company") on trading, and causing the trading of, the Company's securities or securities of certain other publicly traded companies while in possession of confidential information. This Policy is divided into two parts: the first part provid

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2025 XOMA ROYALTY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-39801 52-2154066 (State or Other Jurisdiction of Incorporation) (Commission Fil

Subsidiaries of the Company

Exhibit 21.1 Subsidiaries of the Company Jurisdiction of Organization XOMA Technology Ltd. Bermuda XOMA (US) LLC Delaware XOMA UK Limited United Kingdom XRL 1 LLC Delaware Kinnate Biopharma Inc. Delaware Pulmokine, Inc. Delaware

Amendment No. 1, dated June 3, 2024, to the Royalty Purchase Agreement, dated as of June 21, 2023, by and between XOMA (US) LLC and LadRx Corporation

Exhibit 10.34 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED (INDICATED BY: [***]) FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE OF INFORMATION THAT THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE OR CONFIDENTIAL EXECUTION VERSION FIRST AMENDMENT OF ROYALTY PURCHASE AGREEMENT This First Amendment of Royalty Purchase Agreement (this “Amendment”) is entered into

Pulmokine, Inc. Financial Statements December 31, 2023

Exhibit 99.2 Pulmokine, Inc. Financial Statements December 31, 2023 Pulmokine, Inc. Index to the Financial Statements December 31, 2023 Page Independent Auditor’s Report 1 - 2 Financial Statements Balance Sheet 3 Statement of Operations 4 Statement of Stockholders’ Equity 5 Statement of Cash Flows 6 Notes to the Financial Statements 7 - 12 INDEPENDENT AUDITOR’S REPORT To the Board of Directors and

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 26, 2024 XOMA ROYALTY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-39801 52-2154066 (State or Other Jurisdiction of Incorpo

UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION

Exhibit 99.4 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION On November 26, 2024, XOMA Royalty Corporation (the “Company” or “XOMA”) completed the acquisition (“Transaction”) of Pulmokine, Inc. (“Pulmokine”), pursuant to an Agreement and Plan of Merger, dated as of November 26, 2024 (the “Merger Agreement”), by and among Pulmokine, the Company and XRA 2 Corp (“XRA”), a wholly owned s

Pulmokine, Inc. Financial Statements September 30, 2024

Exhibit 99.3 Pulmokine, Inc. Financial Statements September 30, 2024 Pulmokine, Inc. Index to the Financial Statements September 30, 2024 Page Financial Statements Independent Auditor’s Review Report 1 Financial Statements Balance Sheet 2 Statement of Operations 3 Statement of Stockholders’ Equity 4 Statement of Cash Flows 5 Notes to the Financial Statements 6 - 10 Independent Auditor’s Review Rep

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): November 26, 2024 XOMA ROYALTY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-39801 52-2154066 (State or Other Jurisdiction of Incorporation) (Commission

XOMA Royalty Acquires Pulmokine for $20 Million Adding the Royalty and Milestone Interest in Seralutinib, a Phase 3 Asset, to Its Portfolio Seralutinib becomes XOMA Royalty’s seventh Phase 3 royalty asset, further building the late-stage pipeline bey

Exhibit 99.1 XOMA Royalty Acquires Pulmokine for $20 Million Adding the Royalty and Milestone Interest in Seralutinib, a Phase 3 Asset, to Its Portfolio Seralutinib becomes XOMA Royalty’s seventh Phase 3 royalty asset, further building the late-stage pipeline beyond its six current commercial royalty assets Seralutinib is being developed and co-commercialized by Gossamer Bio, Inc., and Chiesi Farm

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2024 XOMA ROYALTY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-39801 52-2154066 (State or Other Jurisdiction of Incorporation) (Commission F

XOMA Royalty Reports Third Quarter 2024 Financial Results and Highlights Recent Activities Zevra’s MIPLYFFA™ (arimoclomol) received FDA approval and became the sixth commercial asset in XOMA Royalty’s portfolio XOMA Royalty acquired a 50 percent econ

Exhibit 99.1 XOMA Royalty Reports Third Quarter 2024 Financial Results and Highlights Recent Activities Zevra’s MIPLYFFA™ (arimoclomol) received FDA approval and became the sixth commercial asset in XOMA Royalty’s portfolio XOMA Royalty acquired a 50 percent economic interest in TWIST Bioscience’s portfolio of 60-plus licensed early-stage assets across approximately 30 partners Cash receipts total

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-3980

XOMA Royalty Significantly Expands its Royalty and Milestone Portfolio with the Addition of Over 60 Early-Stage Programs from Twist Bioscience XOMA Royalty has acquired 50 percent of Twist’s existing royalty and milestone economics for $15 million XO

Exhibit 99.1 XOMA Royalty Significantly Expands its Royalty and Milestone Portfolio with the Addition of Over 60 Early-Stage Programs from Twist Bioscience XOMA Royalty has acquired 50 percent of Twist’s existing royalty and milestone economics for $15 million XOMA Royalty’s portfolio now holds over 100 assets ranging from revenue-generating commercial therapeutics to pre-clinical programs EMERYVI

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): October 21, 2024 XOMA ROYALTY CORPORATION (Exact Name of Registrant as Specified in Charter) DELAWARE 001-39801 52-2154066 (State or Other Jurisdiction of Incorporation) (Commission F

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): September 20, 2024 XOMA ROYALTY C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): September 20, 2024 XOMA ROYALTY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-39801 52-2154066 (State or Other Jurisdiction of Incorporation) (Commission

Zevra’s MIPLYFFA™ (arimoclomol) Receives Approval from U.S. Food and Drug Administration for Use in Patients with Niemann-Pick Disease Type C (NPC) MIPLYFFA™ is the first therapy approved for use in patients with NPC, a rare genetic disorder XOMA Roy

EX-99.1 Exhibit 99.1 Zevra’s MIPLYFFA™ (arimoclomol) Receives Approval from U.S. Food and Drug Administration for Use in Patients with Niemann-Pick Disease Type C (NPC) MIPLYFFA™ is the first therapy approved for use in patients with NPC, a rare genetic disorder XOMA Royalty is entitled to receive a mid-single digit royalty on MIPLYFFA™ sales and up to $52.6 million in milestones MIPLYFFA™ is now

Landlord Consent to Assignment and Assumption of Lease dated February 1, 2024 by and among Presidio Trust, Kinnate Biopharma Inc., and Eventbrite, Inc.

Exhibit 10.3 LANDLORD CONSENT TO ASSIGNMENT AND ASSUMPTION OF LEASE THIS LANDLORD CONSENT TO ASSIGNMENT AND ASSUMPTION OF LEASE (“Consent Agreement”) is entered into as of February 1, 2024 (the “Effective Date”), by and among the PRESIDIO TRUST, a wholly-owned government corporation of the United States of America (“Landlord”), KINNATE BIOPHARMA INC., a Delaware corporation (“Assignor”), and EVENT

Net Office Lease dated August 5, 2021 between Presidio Trust and Kinnate Biopharma Inc.

Exhibit 10.1 THE PRESIDIO SAN FRANCISCO, CALIFORNIA NET OFFICE LEASE BASIC LEASE INFORMATION Lease Date: August 5, 2021 | 9:53:40 PM PDT Landlord: PRESIDIO TRUST, a wholly-owned government corporation of the United States of America Tenant: KINNATE BIOPHARMA INC., a Delaware corporation Tenant’s Address for Notices: Before Delivery Date: Kinnate Biopharma Inc. 3611 Valley Centre Drive, Suite 175 S

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): August 13, 2024 XOMA ROYALTY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-39801 52-2154066 (State or Other Jurisdiction of Incorporation) (Commission Fi

XOMA Royalty Reports Second Quarter 2024 Financial Results and Highlights Recent Activities Cash receipts totaled $22.6 million in 2Q24, inclusive of royalty income and milestones from Day One Pharmaceuticals and Rezolute Expanded the commercial roya

Exhibit 99.1 XOMA Royalty Reports Second Quarter 2024 Financial Results and Highlights Recent Activities Cash receipts totaled $22.6 million in 2Q24, inclusive of royalty income and milestones from Day One Pharmaceuticals and Rezolute Expanded the commercial royalty and milestone portfolio with the acquisition of economic interests in XACIATO™ (clindamycin phosphate) vaginal gel 2%, and two novel

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39801 XOM

Letter Agreement dated August 26, 2021 between Presidio Trust and Kinnate Biopharma Inc.

Exhibit 10.2 August 26, 2021 Kinnate Biopharma Inc. 103 Montgomery Street, Suite 150 The Presidio of San Francisco San Francisco, California 94129 Attn: Nima Farzan Re: Net Office Lease, dated as of August 5, 2021 (the “Lease”) by and between Kinnate Biopharma Inc., a Delaware corporation, as Tenant, and the Presidio Trust, as Landlord, for the Premises known as Building 103, Suite 150, located at

Certificate of Amendment to the Certificate of Incorporation of the Company

Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE AMENDED CERTIFICATE OF INCORPORATION OF XOMA CORPORATION XOMA Corporation (the “Corporation”), a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “General Corporation Law”), does hereby certify as follows: 1. That the current name of the Corporation is XOMA Corporation.

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): July 8, 2024 XOMA CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-39801 52-2154066 (State or Other Jurisdiction of Incorporation) (Commission File Number)

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 3, 2024 XOMA CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-39801 52-2154066 (State or Other Jurisdiction of Incorporation) (Com

June 13, 2024

June 13, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.

UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION

Exhibit 99.5 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION On April 3, 2024, XOMA Corporation (the “Company” or XOMA”) completed the previously announced acquisition (“Transaction”) of Kinnate Biopharma Inc. (“Kinnate”), pursuant to an Agreement and Plan of Merger, dated as of February 16, 2024 (the “Merger Agreement”), by and among Kinnate, the Company and XRA 1 Corp (“XRA”), a who

June 13, 2024

June 13, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.

TABLE OF CONTENTS Page Condensed Consolidated Balance Sheet (Unaudited) 2 Condensed Consolidated Statement of Operations and Comprehensive Loss (Unaudited) 3 Condensed Consolidated Statement of Stockholders’ Equity (Unaudited) 4 Condensed Consolidate

Exhibit 99.2 TABLE OF CONTENTS Page Condensed Consolidated Balance Sheet (Unaudited) 2 Condensed Consolidated Statement of Operations and Comprehensive Loss (Unaudited) 3 Condensed Consolidated Statement of Stockholders’ Equity (Unaudited) 4 Condensed Consolidated Statement of Cash Flows (Unaudited) 5 Notes to Unaudited Condensed Consolidated Financial Statements 6 1 KINNATE BIOPHARMA INC. CONDENS

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): May 30, 2024 XOMA CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-39801 52-2154066 (State or Other Jurisdiction of Incorporation) (Commission File Number)

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): May 15, 2024 XOMA CORPORATION (Exact Name of Registrant as Specified in Charter) DELAWARE 001-39801 52-2154066 (State or Other Jurisdiction of Incorporation) (Commission File Number)

Abu Dhabi • Beijing • Brussels • Century City • Dallas • Denver • Dubai • Frankfurt • Hong Kong • Houston • London • Los Angeles Munich • New York • Orange County • Palo Alto • Paris • Riyadh • San Francisco • Singapore • Washington, D.C.

Gibson, Dunn & Crutcher LLP One Embarcadero Center, Suite 2600 San Francisco, CA 94111-3715 Tel 415.

Amendment No. 1 to Royalty Purchase Agreement entered into as of March 4, 2024 by and between Viracta

Exhibit 10.3 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED (INDICATED BY: [***]) FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE OF INFORMATION THAT THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE OR CONFIDENTIAL AMENDMENT NO. 1 TO ROYALTY PURCHASE AGREEMENT This Amendment No. 1 to Royalty Purchase Agreement (this “Amendment”) is entered into as of March 4, 2024

Talphera, Inc. and XOMA (US) LLC dated as of January 12, 2024

Exhibit 10.2 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED (INDICATED BY: [***]) FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE OF INFORMATION THAT THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE OR CONFIDENTIAL. Payment Interest Purchase Agreement By and Between TALPHERA, INC. and xoma (us) llc Dated as of JANUARY 12, 2024 TABLE OF CONTENTS Page ARTICLE I DEFI

XOMA Reports First Quarter 2024 Financial Results and Highlights Recent Activities Earned $9 million milestone upon U.S. Food and Drug Administration’s approval of Day One’s OJEMDA™ (tovorafenib); XOMA is entitled to receive a mid-single digit royalt

Exhibit 99.1 XOMA Reports First Quarter 2024 Financial Results and Highlights Recent Activities Earned $9 million milestone upon U.S. Food and Drug Administration’s approval of Day One’s OJEMDA™ (tovorafenib); XOMA is entitled to receive a mid-single digit royalty on OJEMDA™ sales Acquired Kinnate Pharmaceuticals, adding at least $9.5 million in non-dilutive capital to XOMA’s balance sheet Expande

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39801 XO

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): May 9, 2024 XOMA CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-39801 52-2154066 (State or Other Jurisdiction of Incorporation) (Commission File Number) (

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): April 29, 2024 XOMA CORPORATION (Exact Name of Registrant as Specified in Charter) DELAWARE 001-39801 52-2154066 (State or Other Jurisdiction of Incorporation) (Commission File Number

XOMA Adds Economic Interests in Three First-in-Category Assets to its Royalty and Milestone Portfolio Including XACIATO™ (clindamycin phosphate) Vaginal Gel 2% Organon, a global women’s healthcare company, initiated XACIATO™ commercial activities in

Exhibit 99.1 XOMA Adds Economic Interests in Three First-in-Category Assets to its Royalty and Milestone Portfolio Including XACIATO™ (clindamycin phosphate) Vaginal Gel 2% Organon, a global women’s healthcare company, initiated XACIATO™ commercial activities in the fourth quarter of 2023 XOMA further expands its late-stage portfolio with synthetic royalty and milestone interests in two additional

XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG) XOMA is entitled to a mid-single digit royalty on global OJEMDA™ sales Fi

Exhibit 99.1 XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG) XOMA is entitled to a mid-single digit royalty on global OJEMDA™ sales First and only FDA-approved type II RAF inhibitor for patients with relapsed or refractory pLGG harboring a BRAF fusion or rearrangement, o

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): April 25, 2024 XOMA CORPORATION (Exact Name of Registrant as Specified in Charter) DELAWARE 001-39801 52-2154066 (State or Other Jurisdiction of Incorporation) (Commission File Number

Abu Dhabi • Beijing • Brussels • Century City • Dallas • Denver • Dubai • Frankfurt • Hong Kong • Houston • London • Los Angeles Munich • New York • Orange County • Palo Alto • Paris • Riyadh • San Francisco • Singapore • Washington, D.C.

Gibson, Dunn & Crutcher LLP One Embarcadero Center, Suite 2600 San Francisco, CA 94111-3715 Tel 415.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2) KINNATE BIOPHARMA INC. (Name of Subject Company (Is

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2) KINNATE BIOPHARMA INC. (Name of Subject Company (Issuer)) XRA 1 CORP. (Name of Filing Persons (Offeror)) XOMA CORPORATION (Name of Filing Persons (Parent of Offeror)) Common Stock, Par Value $0.0001 Pe

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 3, 2024 XOMA CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-39801 52-2154066 (State or Other Jurisdiction of Incorporation) (Commission File Number)

Press Release issued by XOMA Corporation on April 3, 2024 (incorporated herein by reference to Exhibit (a)(5)(D) to the Schedule TO-T/A filed by XOMA Corporation on April 3, 2024).

Exhibit (a)(5)(D) XOMA Corporation Announces Closing of Tender Offer Kinnate Stockholders to Receive $2.

Contingent Value Rights Agreement, dated April 3, 2024, by and between the Company, XRA 1 Corp., Broadridge Corporate Issuer Solutions, LLC and Fortis Advisors LLC.

Exhibit 2.2 Execution Version This CONTINGENT VALUE RIGHTS AGREEMENT, dated as of April 3, 2024 (this “Agreement”), is entered into by and between XOMA Corporation, a Delaware corporation (the “Parent”), XRA 1 Corp., a Delaware corporation and a wholly owned Subsidiary of Parent (the “Purchaser”), Broadridge Corporate Issuer Solutions, LLC, a Pennsylvania limited liability company, as Rights Agent

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒       Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒       Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 1

Abu Dhabi • Beijing • Brussels • Century City • Dallas • Denver • Dubai • Frankfurt • Hong Kong • Houston • London • Los Angeles Munich • New York • Orange County • Palo Alto • Paris • Riyadh • San Francisco • Singapore • Washington, D.C.

Gibson, Dunn & Crutcher LLP One Embarcadero Center, Suite 2600 San Francisco, CA 94111-3715 Tel 415.

XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc. Upon closing, XOMA anticipates adding approximately $9.5 million in cash to its balance sheet and several early-stag

Exhibit (a)(5)(C) XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1) KINNATE BIOPHARMA INC. (Name of Subject Company (Is

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1) KINNATE BIOPHARMA INC. (Name of Subject Company (Issuer)) XRA 1 CORP. (Name of Filing Persons (Offeror)) XOMA CORPORATION (Name of Filing Persons (Parent of Offeror)) Common Stock, Par Value $0.0001 Pe

Amended and Restated Offer to Purchase All Outstanding Shares of Common Stock KINNATE BIOPHARMA INC. A Cash Amount per Share of $2.5879, Consisting of a Base Price Per Share of $2.3352 and an Additional Price Per Share of $0.2527, Plus One Non-Transf

Table of Contents Exhibit (a)(1)(A) Amended and Restated Offer to Purchase All Outstanding Shares of Common Stock of KINNATE BIOPHARMA INC.

Form of Indenture

EX-4.6 Exhibit 4.6 XOMA CORPORATION, Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 20  Debt Securities TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 6 Section 2.01 Designation and Terms of Securities 6 Section 2.02 Form of Securities and Trustee’s Certificate 9 Se

XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Value Raised up to $140 million of non-dilutive non-recourse capital through a royalty-backed loan related to VAB

Exhibit 99.1 XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Value Raised up to $140 million of non-dilutive non-recourse capital through a royalty-backed loan related to VABYSMO® from funds managed by Blue Owl Capital Received $15.5 million in cash payments related to our growing royalty base and the achievem

Sale, Contribution and Servicing Agreement dated as of December 15, 2023 by and among XOMA (US) LLC, as Seller, and solely for purposes of ‎Section 2.03 and ‎Section 4.03(b)(ii) therein, the Company, as Parent, on the one hand and XRL 1 LLC, as Purchaser, on the other hand

Exhibit 10.64 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED (INDICATED BY: [***]) FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE OF INFORMATION THAT THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE OR CONFIDENTIAL. SALE, CONTRIBUTION AND SERVICING AGREEMENT dated as of December 15, 2023 between XOMA (US) LLC, as Seller, and Solely for purposes of ‎Section 2.03 a

Form of Indenture

Exhibit 4.6 XOMA CORPORATION, Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 20  Debt Securities TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 6 Section 2.01 Designation and Terms of Securities 6 Section 2.02 Form of Securities and Trustee’s Certificate 9 Section 2

Description of Registrant’s Securities

Exhibit 4.9 DESCRIPTION OF CAPITAL STOCK The following is a description of the Common Stock, $0.0075 par value (the “Common Stock”), Preferred Stock, $0.05 par value (the “Preferred Stock”) and depositary shares of XOMA Corporation (“we,” “us,” “our” or the “Company”). The Common Stock, 8.625% Series A Cumulative Perpetual Preferred Stock, $0.05 par value (the “Series A Preferred Stock”), and the

Subsidiaries of the Company

Exhibit 21.1 Subsidiaries of the Company Jurisdiction of Organization XOMA Technology Ltd. Bermuda XOMA (US) LLC Delaware XOMA UK Limited United Kingdom XRL 1 LLC Delaware

As filed with the Securities and Exchange Commission on March 8, 2024.

Table of Contents As filed with the Securities and Exchange Commission on March 8, 2024.

Office Lease dated June 27, 2023 between KBSIII Towers at Emeryville, LLC and XOMA (US) LLC

Exhibit 10.65 SECOND AMENDMENT TO OFFICE LEASE This SECOND AMENDMENT TO OFFICE LEASE (this “Amendment”), dated as of June 27, 2023 (the “Effective Date”), is entered into by and between KBSIII TOWERS AT EMERYVILLE, LLC, a Delaware limited liability company (“Landlord”), and XOMA (US) LLC, a Delaware limited liability company (“Tenant”). R E C I T A L S: A.Pursuant to that certain Office Lease date

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables S-4 (Form Type) XOMA Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities  Security  Type Security Class Title Fee Calculation  or Carry Forward Rule Amount Registered  Proposed Maximum  Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Registered Securities Fees to Be Paid Equity Common stock, par value $0.

As filed with the Securities and Exchange Commission on March 8, 2024.

Table of Contents As filed with the Securities and Exchange Commission on March 8, 2024.

Incentive Compensation Clawback Policy

Exhibit 97 XOMA Corporation Incentive Compensation Recoupment Policy 1.Introduction The Compensation Committee (the “Compensation Committee”) of the Board of Directors (the “Board”) of XOMA Corporation, a Delaware corporation (the “Company”), has determined that it is in the best interests of the Company and its stockholders to adopt this Incentive Compensation Recoupment Policy (this “Policy”) pr

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables S-3 (Form Type) XOMA Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective date Filing Fee Previously Paid In Connection With Unsold Securities to be Carried Forward Newly Registered Securities Fees to Be Paid Equity  Common stock, par  value $0.

Amended and Restated Officer Employment Agreement, dated January 8, 2024, between XOMA Corporation and Owen Hughes

Exhibit 10.16 AMENDED AND RESTATED OFFICER EMPLOYMENT AGREEMENT This Amended and Restated Officer Employment Agreement (“Agreement”) between Owen Hughes (“Employee”) and XOMA Corporation (“XOMA” or “the Company”) (collectively, the “Parties”) is effective as of January 8, 2024 (the “Agreement Effective Date”). WHEREAS, Employee is currently employed by the Company as its Interim Chief Executive Of

Loan Agreement dated December 15, 2023, between XRL 1 LLC, the lenders from time to time party thereto and Blue Owl Capital Corporation

Exhibit 10.63 THE FOLLOWING INFORMATION IS SUPPLIED SOLELY FOR U.S. FEDERAL INCOME TAX PURPOSES. THE LOAN UNDER THIS AGREEMENT ARE TREATED AS HAVING BEEN ISSUED WITH ORIGINAL ISSUE DISCOUNT (“OID”) WITHIN THE MEANING OF SECTION 1273 OF THE INTERNAL REVENUE CODE OF 1986, AS AMENDED (THE “CODE”), AND THIS LEGEND IS REQUIRED BY SECTION 1275(c) OF THE CODE. INFORMATION INCLUDING THE ISSUE PRICE, THE A

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): March 8, 2024 XOMA CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-39801 52-2154066 (State or Other Jurisdiction of Incorporation) (Commission File Number)

Letter Amendment to Officer Employment Agreement dated November 1, 2022, between XOMA Corporation and Thomas Burns

Exhibit 10.10 November 1, 2022 Thomas Burns VIA EMAIL/DOCUSIGN Dear Thomas: As you know, you are employed by XOMA Corporation (the “Company”) pursuant to the terms of an Officer Employment Agreement dated August 7, 2017, as amended on April 1, 2022 (the “Agreement”). You and the Company are hereby agreeing to amend the Agreement to modify the retention benefit contained therein, as set forth below

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39801 XOMA CO

Offer to Purchase All Outstanding Shares of Common Stock KINNATE BIOPHARMA INC. A Cash Amount per Share between $2.3352 and $2.5879, Consisting of a Base Price Per Share of $2.3352 and an Additional Price Per Share of up to $0.2527, Plus One Non-Tran

Table of Contents Exhibit (a)(1)(A) Offer to Purchase All Outstanding Shares of Common Stock of KINNATE BIOPHARMA INC.

MUTUAL CONFIDENTIAL DISCLOSURE AGREEMENT

Exhibit (d)(2) MUTUAL CONFIDENTIAL DISCLOSURE AGREEMENT This Mutual Confidential Disclosure Agreement (this “Agreement”), effective as of November 11, 2023 (the “Effective Date”), is entered into by and between Kinnate Biopharma Inc.

Calculation of Filing Fee Tables SC TO-T (Form Type) KINNATE BIOPHARMA INC. (Name of Subject Company – Issuer) XRA 1 CORP (Names of Filing Persons — Offeror) XOMA CORPORATION (Names of Filing Persons — Parent of Offeror) Table 1: Transaction Valuatio

Exhibit 107 Calculation of Filing Fee Tables SC TO-T (Form Type) KINNATE BIOPHARMA INC.

Letter of Transmittal To Tender Shares of Common Stock KINNATE BIOPHARMA INC. a Delaware corporation A Cash Amount per Share between $2.3352 and $2.5879, Consisting of a Base Price Per Share of $2.3352 and an Additional Price Per Share of up to $0.25

Exhibit (a)(1)(B) Letter of Transmittal To Tender Shares of Common Stock of KINNATE BIOPHARMA INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 KINNATE BIOPHARMA INC. (Name of Subject Company (Issuer)) XRA 1 CORP.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 KINNATE BIOPHARMA INC. (Name of Subject Company (Issuer)) XRA 1 CORP. (Name of Filing Persons (Offeror)) XOMA CORPORATION (Name of Filing Persons (Parent of Offeror)) Common Stock, Par Value $0.0001 Per Share (Title of

Offer to Purchase All Outstanding Shares of Common Stock KINNATE BIOPHARMA INC. A Cash Amount per Share between $2.3352 and $2.5879, Consisting of a Base Price Per Share of $2.3352 and an Additional Price Per Share of up to $0.2527, Plus One Non-Tran

Exhibit (a)(1)(D) Offer to Purchase All Outstanding Shares of Common Stock of KINNATE BIOPHARMA INC.

Offer to Purchase All Outstanding Shares of Common Stock KINNATE BIOPHARMA INC. A Delaware corporation A Cash Amount per Share between $2.3352 and $2.5879, Consisting of a Base Price Per Share of $2.3352 and an Additional Price Per Share of up to $0.

Exhibit (a)(1)(C) Offer to Purchase All Outstanding Shares of Common Stock of KINNATE BIOPHARMA INC.

XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right Upon closing, XOMA anticipates adding approximately $9.5 million in cash to its balance sheet and several early-st

Exhibit 99.1 XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right Upon closing, XOMA anticipates adding approximately $9.5 million in cash to its balance sheet and several early-stage programs to potentially add to its royalty portfolio EMERYVILLE, Calif., February 16, 2024 (GLOBE NEWSWIRE) – XOMA Corporation (NASDA

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Rule 14d-100) TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 KINNATE BIOPHARMA INC. (Name of Subject Company (Issue

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Rule 14d-100) TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 KINNATE BIOPHARMA INC. (Name of Subject Company (Issuer)) XRA 1 CORP. (Name of Filing Persons (Offeror 1)) XOMA CORPORATION (Name of Filing Persons (Parent of Offeror)) Common Stock, Par Value $0.0001 Per

Agreement and Plan of Merger between the Company, Kinnate and Merger Sub, dated February 16, 2024

Exhibit 2.1 Final Form AGREEMENT AND PLAN OF MERGER DATED AS OF FEBRUARY 16, 2024 AMONG XOMA CORPORATION XRA 1 CORP. AND KINNATE BIOPHARMA INC. TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 2    SECTION 1.01 Definitions 2 SECTION 1.02 Interpretation and Rules of Construction 12 ARTICLE II THE OFFER 13 SECTION 2.01 The Offer 13 SECTION 2.02 Company Actions 16 ARTICLE III THE MERGER 17 SECTION 3.01 T

XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right Upon closing, XOMA anticipates adding approximately $9.5 million in cash to its balance sheet and several early-st

Exhibit 99.1 XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right Upon closing, XOMA anticipates adding approximately $9.5 million in cash to its balance sheet and several early-stage programs to potentially add to its royalty portfolio EMERYVILLE, Calif., February 16, 2024 (GLOBE NEWSWIRE) – XOMA Corporation (NASDA

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): February 16, 2024 XOMA CORPORATION (Exact Name of Registrant as Specified in Charter) DELAWARE 001-39801 52-2154066 (State or Other Jurisdiction of Incorporation) (Commission File Num

JOINT FILING AGREEMENT

Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D dated January 16, 2024 (including amendments thereto) with respect to the shares of Common Stock, $0.0075 par value, of XOMA Corporation, a Delaware corporation.

XOMA / XOMA Corporation / BIOTECHNOLOGY VALUE FUND L P - AMENDMENT NO. 10 TO SCHEDULE 13D Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 10)1 XOMA Corporation (Name of Issuer) Common Stock, $0.0075 par value (Title of Class of Securities) 98419J 206 (CUSIP Number) JAMES KRATKY BVF PARTNERS L

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): January 7, 2024 XOMA CORPORATION

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): January 7, 2024 XOMA CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-39801 52-2154066 (State or Other Jurisdiction of Incorporation) (Commission File Numbe

XOMA Announces Stock Repurchase Program of up to $50 Million Balanced capital allocation strategy looks to return capital to shareholders while continuing to invest in royalty and milestone acquisitions that will drive total shareholder return

EX-99.1 Exhibit 99.1 XOMA Announces Stock Repurchase Program of up to $50 Million Balanced capital allocation strategy looks to return capital to shareholders while continuing to invest in royalty and milestone acquisitions that will drive total shareholder return EMERYVILLE, Calif., January 2, 2024 (GLOBE NEWSWIRE) – XOMA Corporation (Nasdaq: XOMA), the biotech royalty aggregator, today announced

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): January 2, 2024 XOMA CORPORATION

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): January 2, 2024 XOMA CORPORATION (Exact Name of Registrant as Specified in Charter) DELAWARE 001-39801 52-2154066 (State or Other Jurisdiction of Incorporation) (Commission File Numbe

Form of Warrant (December 2023) ($42.50 Exercise Price)

Exhibit 4.2 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR, IN THE OPINION OF LEGAL COUNSEL IN FORM AND SUBSTAN

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): December 15, 2023 XOMA CORPORATIO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): December 15, 2023 XOMA CORPORATION (Exact Name of Registrant as Specified in Charter) DELAWARE 001-39801 52-2154066 (State or Other Jurisdiction of Incorporation) (Commission File Num

Form of Warrant (December 2023) ($50.00 Exercise Price)

Exhibit 4.3 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR, IN THE OPINION OF LEGAL COUNSEL IN FORM AND SUBSTAN

Form of Warrant (December 2023) ($35.00 Exercise Price)

Exhibit 4.1 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR, IN THE OPINION OF LEGAL COUNSEL IN FORM AND SUBSTAN

XOMA Raises up to $140 Million in Non-Dilutive, Non-Recourse Financing from Funds Managed by Blue Owl Capital Backed by VABYSMO® Royalties Low-cost financing capitalizes on XOMA’s $14 million acquisition of VABYSMO® (faricimab) royalties in 2021 Proc

Exhibit 99.1 XOMA Raises up to $140 Million in Non-Dilutive, Non-Recourse Financing from Funds Managed by Blue Owl Capital Backed by VABYSMO® Royalties Low-cost financing capitalizes on XOMA’s $14 million acquisition of VABYSMO® (faricimab) royalties in 2021 Proceeds expected to be used for stock repurchases and additional royalty and milestone acquisitions Financing from Blue Owl extends XOMA’s c

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-39801 XO

XOMA Reports Third Quarter 2023 Financial Results and Highlights Upcoming Events Expected to Drive Shareholder Value Received $6.6 million in cash receipts during the quarter related to our growing royalty base and certain development milestones One

Exhibit 99.1 XOMA Reports Third Quarter 2023 Financial Results and Highlights Upcoming Events Expected to Drive Shareholder Value Received $6.6 million in cash receipts during the quarter related to our growing royalty base and certain development milestones One New Drug Application (NDA) was filed in the third quarter; another is anticipated prior to year-end Company anticipates the initiation of

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): November 7, 2023 XOMA CORPORATION (Exact Name of Registrant as Specified in Charter) DELAWARE 001-39801 52-2154066 (State or Other Jurisdiction of Incorporation) (Commission File Numb

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): October 31, 2023 XOMA CORPORATION (Exact Name of Registrant as Specified in Charter) DELAWARE 001-39801 52-2154066 (State or Other Jurisdiction of Incorporation) (Commission File Numb

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): October 23, 2023 XOMA CORPORATION (Exact Name of Registrant as Specified in Charter) DELAWARE 001-39801 52-2154066 (State or Other Jurisdiction of Incorporation) (Commission File Numb

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): September 11, 2023 XOMA CORPORATI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): September 11, 2023 XOMA CORPORATION (Exact Name of Registrant as Specified in Charter) DELAWARE 001-39801 52-2154066 (State or Other Jurisdiction of Incorporation) (Commission File Nu

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): August 25, 2023 XOMA CORPORATION (Exact Name of Registrant as Specified in Charter) DELAWARE 001-39801 52-2154066 (State or Other Jurisdiction of Incorporation) (Commission File Numbe

Assignment and Assumption Agreement, dated as of June 21, 2023, by and between XOMA (US) LLC and LadRx Corporation

Exhibit 10.3 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED (INDICATED BY: [***]) FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE OF INFORMATION THAT THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE OR CONFIDENTIAL. ASSIGNMENT AND ASSUMPTION AGREEMENT This ASSIGNMENT AND ASSUMPTION AGREEMENT (this “Agreement”), dated as of June 21, 2023 (the “Closing Date”), is ma

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): August 8, 2023 XOMA CORPORATION (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): August 8, 2023 XOMA CORPORATION (Exact Name of Registrant as Specified in Charter) DELAWARE 001-39801 52-2154066 (State or Other Jurisdiction of Incorporation) (Commission File Number

Royalty Purchase Agreement, dated as of June 21, 2023, by and between XOMA (US) LLC and LadRx Corporation

Exhibit 10.4 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED (INDICATED BY: [***]) FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE OF INFORMATION THAT THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE OR CONFIDENTIAL. Royalty Purchase Agreement By and Between LadRx Corporation and XOMA (US) LLC Dated as of June 21, 2023 Table of Contents Page Article 1 DEFINED TERMS

XOMA Reports Second Quarter 2023 Financial Results and Provides Update on its Royalty Monetization Strategy Completed two royalty acquisitions in the first half of 2023 adding one cash flow generating asset, one NDA-ready asset, and a Phase 2 asset T

EX-99.1 Exhibit 99.1 XOMA Reports Second Quarter 2023 Financial Results and Provides Update on its Royalty Monetization Strategy Completed two royalty acquisitions in the first half of 2023 adding one cash flow generating asset, one NDA-ready asset, and a Phase 2 asset Two portfolio assets are now generating cash flows from commercial sales Company expects at least one partner to file a New Drug A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-39801 XOMA Co

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): July 18, 2023 XOMA CORPORATION (E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): July 18, 2023 XOMA CORPORATION (Exact Name of Registrant as Specified in Charter) DELAWARE 001-39801 52-2154066 (State or Other Jurisdiction of Incorporation) (Commission File Number)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): June 21, 2023 XOMA CORPORATION (E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): June 21, 2023 XOMA CORPORATION (Exact Name of Registrant as Specified in Charter) DELAWARE 001-39801 52-2154066 (State or Other Jurisdiction of Incorporation) (Commission File Number)

Form of Performance Stock Unit Agreement under the Amended and Restated 2010 Long Term Incentive and Stock Award Plan

EX-10.1 Exhibit 10.1 Performance Unit Agreement XOMA Corporation Amended and Restated 2010 Long Term Incentive and Stock Award Plan (A) Recipient: (B) Grant Date: (C) Target Shares: (D) Grant Number: Vesting Schedule: As set forth in Attachment I. XOMA Corporation (the “Company”) has awarded you Performance Units (the “Performance Units”) to receive up to the number of Target Shares shown in item

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 17, 2023 XOMA CORPORATION (Exact Name of Registrant as Specified in Charter) DELAWARE 001-39801 52-2154066 (State or Other Jurisdiction of Incorporation) (Commission File Number)

As filed with the U.S. Securities and Exchange Commission on May 18, 2023

As filed with the U.S. Securities and Exchange Commission on May 18, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 XOMA CORPORATION (Exact name of registrant as specified in its charter) Delaware 52-2154066 (State or other jurisdiction of (I.R.S. Employer incorporation or organizat

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) XOMA Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): May 9, 2023 XOMA CORPORATION (Exact Name of Registrant as Specified in Charter) DELAWARE 001-39801 52-2154066 (State or Other Jurisdiction of Incorporation) (Commission File Number) (

Payment Interest Purchase Agreement, dated March 29, 2023, by and between Aptevo Therapeutics Inc. and XOMA (US) LLC

Executed Version Exhibit 10.7 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED (INDICATED BY: [***]) FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE OF INFORMATION THAT THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE OR CONFIDENTIAL. Payment Interest Purchase Agreement By and Between Aptevo therapeutics Inc. and xoma (us) llc Dated as of MARCH 29, 2023 Table of Con

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-39801 XOMA C

XOMA Reports First Quarter 2023 Financial Results and Provides Update on the Acceleration of its Differentiated Royalty Monetization Strategy First quarter with incoming cashflows from two commercial assets Completed first royalty asset acquisition u

EX-99.1 Exhibit 99.1 XOMA Reports First Quarter 2023 Financial Results and Provides Update on the Acceleration of its Differentiated Royalty Monetization Strategy First quarter with incoming cashflows from two commercial assets Completed first royalty asset acquisition under new leadership EMERYVILLE, Calif. – May 9, 2023 (GLOBE NEWSWIRE) – XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggr

XOMA Corporation Amended and Restated 2010 Long Term Incentive and Stock Award Plan

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as p erm itte d by Rule 14a-6(e)(2)) ☒ Definit

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): March 29, 2023 XOMA CORPORATION (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): March 29, 2023 XOMA CORPORATION (Exact Name of Registrant as Specified in Charter) DELAWARE 001-39801 52-2154066 (State or Other Jurisdiction of Incorporation) (Commission File Number

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): March 21, 2023 XOMA CORPORATION (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): March 21, 2023 XOMA CORPORATION (Exact Name of Registrant as Specified in Charter) DELAWARE 001-39801 52-2154066 (State or Other Jurisdiction of Incorporation) (Commission File Number

License Agreement, dated July 26, 2021, between ObsEva, SA and Organon International GmbH

Exhibit 10.57 [*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. LICENSE AGREEMENT (EBOPIPRANT) This License Agreement (the “Agreement”) is entered into as of July 26, 2021 (the “Effective Date”), by and between ObsEva SA, having an address

The Amended Retention and Severance Plan dated, October 25, 2022

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.

Letter Amendment to Officer Employment Agreement dated November 1, 2022, between the Company and Thomas Burns

Exhibit 10.10 November 1, 2022 Thomas Burns VIA EMAIL/DOCUSIGN Dear Thomas: As you know, you are employed by XOMA Corporation (the “Company”) pursuant to the terms of an Officer Employment Agreement dated August 7, 2017, as amended on April 1, 2022 (the “Agreement”). You and the Company are hereby agreeing to amend the Agreement to modify the retention benefit contained therein, as set forth below

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39801 XOMA COR

Officer Employment Agreement, dated January 3, 2023, between XOMA Corporation and Bradley Sitko

Exhibit 10.16 OFFICER EMPLOYMENT AGREEMENT This Officer Employment Agreement (“Agreement”) between Bradley Sitko (“Employee”) and XOMA Corporation (“XOMA” or “the Company”) (collectively, the “Parties”) is effective as of January 3, 2023 (the “Agreement Effective Date”). 1.Employment. Employee’s employment with XOMA in the position of Chief Investment Officer shall commence on the Agreement Effect

Officer Employment Agreement, dated January 3, 2023, between XOMA Corporation and Owen Hughes

Exhibit 10.15 OFFICER EMPLOYMENT AGREEMENT This Officer Employment Agreement (“Agreement”) between Owen Hughes (“Employee”) and XOMA Corporation (“XOMA” or “the Company”) (collectively, the “Parties”) is effective as of January 1, 2023 (the “Agreement Effective Date”). 1.Employment. Employee’s employment with XOMA in the position of Executive Chairman and Interim Chief Executive Officer shall comm

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): March 9, 2023 XOMA CORPORATION (Exact Name of Registrant as Specified in Charter) DELAWARE 001-39801 52-2154066 (State or Other Jurisdiction of Incorporation) (Commission File Number)

License Agreement, dated June 10, 2015, between ObsEva, SA and Ares Trading S.A.

Exhibit 10.58 [*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. LICENSE AGREEMENT Dated June 10, 2015 By and Between ARES TRADING S.A. And OBSEVA S.A. LICENSE AGREEMENT This License Agreement (the “Agreement”) is dated as of June 10, 2015

XOMA Reports Full-Year 2022 Financial Results and Provides Update to the Acceleration of its Differentiated Royalty Monetization Strategy 2022 was the first year with cash receipts from a commercial asset since becoming a royalty aggregator Ebopipran

EX-99.1 Exhibit 99.1 XOMA Reports Full-Year 2022 Financial Results and Provides Update to the Acceleration of its Differentiated Royalty Monetization Strategy 2022 was the first year with cash receipts from a commercial asset since becoming a royalty aggregator Ebopiprant royalty and milestone license acquisition gives XOMA the potential to earn up to $378 million, net, in milestones plus mid-sing

Intellectual Property Acquisition Agreement, dated November 21, 2022 between XOMA Corporation and ObsEva, SA

Execution Version Exhibit 10.56 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential. IP ACQUISITION AGREEMENT This IP ACQUISITION AGREEMENT (this “Agreement”), dated as of November 21, 2022 (the “Effective Date”), is made by and between

Description of Registrant’s Securities

Exhibit 4.6 DESCRIPTION OF XOMA CORPORATION CAPITAL STOCK The following is a description of the Common Stock, $0.0075 par value (the “Common Stock”), Preferred Stock, $0.05 par value (the “Preferred Stock”) and depositary shares of XOMA Corporation (the “Company”). The Common Stock, 8.625% Series A Cumulative Perpetual Preferred Stock (the “Series A Preferred Stock”) and the depositary shares (the

Subsidiaries of the Company

Exhibit 21.1 Subsidiaries of the Company Jurisdiction of Organization XOMA Technology Ltd. Bermuda XOMA (US) LLC Delaware XOMA UK Limited United Kingdom

Inducement Stock Option Agreement, by and between XOMA Corporation and Bradley Sitko

EX-99.5 Exhibit 99.5 Stock Option Agreement XOMA Corporation Inducement Grant Outside of the Amended and Restated 2010 Long Term Incentive and Stock Award Plan (A) Optionee: BRADLEY SITKO [***] [***] Employee ID: 200118 (B) Grant Date: January 03, 2023 (C) Shares: 250,000 (D) Share Installments: VESTING DATE SHARES VESTING VEST TYPE January 03, 2024 62,500 On Vest Date January 03, 2027 187,500 Mon

Filing Fee Table

EX-FILING FEES Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) XOMA Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.

Inducement Stock Option Agreement, by and between XOMA Corporation and Bradley Sitko

EX-99.4 Exhibit 99.4 Stock Option Agreement XOMA Corporation Inducement Grant Outside of the Amended and Restated 2010 Long Term Incentive and Stock Award Plan (A) Optionee: BRADLEY SITKO [***] [***] Employee ID: 200118 (B) Grant Date: January 03, 2023 (C) Shares: 300,000 (D) Share Installments: VESTING DATE SHARES VESTING VEST TYPE January 03, 2024 75,000 On Vest Date January 03, 2027 225,000 Mon

As filed with the Securities and Exchange Commission on January 30, 2023

S-8 As filed with the Securities and Exchange Commission on January 30, 2023 Registration No.

Inducement Stock Option Agreement, by and between XOMA Corporation and Owen Hughes

EX-99.3 Exhibit 99.3 Stock Option Agreement XOMA Corporation Inducement Grant Outside of the Amended and Restated 2010 Long Term Incentive and Stock Award Plan (A) Optionee: OWEN HUGHES [***] [***] Employee ID: 200117 (B) Grant Date: January 03, 2023 (C) Shares: 75,000 (D) Share Installments: VESTING DATE SHARES VESTING VEST TYPE January 01, 2026 75,000 Monthly (E) Option Number: 007394 (F) Expira

Inducement Stock Option Agreement, by and between XOMA Corporation and Owen Hughes

EX-99.2 Exhibit 99.2 Stock Option Agreement XOMA Corporation Inducement Grant Outside of the Amended and Restated 2010 Long Term Incentive and Stock Award Plan (A)  Optionee: OWEN HUGHES [***] [***] Employee ID: 200117 (B)  Grant Date: January 03, 2023 (C)  Shares: 100,000 (D)  Share Installments: VESTING DATE SHARES VESTING VEST TYPE December 31, 2023 100,000 Quarterly (E)  Option Number: 007393

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 31, 2022 XOMA CORPORATION (Exact Name of Registrant as Specified in Charter) DELAWARE 001-39801 52-2154066 (State or Other Jurisdiction of Incorporation) (Commission File Num

Entry into a Material Definitive Agreement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): November 21, 2022 XOMA CORPORATION (Exact Name of Registrant as Specified in Charter) DELAWARE 001-39801 52-2154066 (State or Other Jurisdiction of Incorporation) (Commission File Num

License Agreement, dated March 23, 2016, between XOMA Corporation and Ology Bioservices Inc. (formerly Nanotherapeutics Inc., now a wholly owned subsidiary of National Resilience, Inc.)

?Exhibit 10.3 [*] = Certain portions of this exhibit (indicated by asterisks) have been omitted as the registrant has determined that the information is both not material and is the type that the registrant treats as private or confidential. ? ? ? ? ? ? ? NANOTHERAPEUTICS LICENSE AGREEMENT, BY AND BETWEEN XOMA (US) LLC and NANOTHERAPEUTICS, INC. March 23, 2016 ? ? ? ? 276626674 v2 ? ? ?EXECUTION C

Amendment and Restatement, dated February 2, 2017, to the Asset Purchase Agreement, dated November 4, 2015, and License Agreement, dated March 23, 2016, between XOMA Corporation and Ology Bioservices Inc. (formerly Nanotherapeutics Inc., now a wholly owned subsidiary of National Resilience, Inc.)

Exhibit 10.4 [*] = Certain portions of this exhibit (indicated by asterisks) have been omitted as the registrant has determined that the information is both not material and is the type that the registrant treats as private or confidential. Amendment and Restatement to Agreements This Amendment and Restatement (?Amendment?) to both the Asset Purchase Agreement (?APA?) and Nanotherapeutics License

License Agreement, dated August 24, 2017, by and between XOMA Corporation and Novartis Pharma AG

Exhibit 10.2 [*] = Certain portions of this exhibit (indicated by asterisks) have been omitted as the registrant has determined that the information is both not material and is the type that the registrant treats as private or confidential. ? ? ? ? ? ? ? ? LICENSE AGREEMENT ? by and between XOMA (US) LLC and ? NOVARTIS PHARMA AG ? 276626894 v2 ? ? ? ? ? ?CONFIDENTIAL TABLE OF CONTENTS ARTICLE I DE

XOMA Reports Third Quarter 2022 Financial Results and Highlights Recent Operational Events Received first recurring royalty-style payment from Roche related to faricimab, its newly launched therapy for wet age-related macular degeneration (wAMD) and

Exhibit 99.1 XOMA Reports Third Quarter 2022 Financial Results and Highlights Recent Operational Events Received first recurring royalty-style payment from Roche related to faricimab, its newly launched therapy for wet age-related macular degeneration (wAMD) and diabetic macular edema (DME). First five months of sales in the U.S. and initial sales in Japan resulted in a $0.5 million cash payment t

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

IL-1b Target License Agreement, dated August 24, 2017, by and between XOMA Corporation and Novartis Pharma AG

Exhibit 10.1 ? [*] = Certain portions of this exhibit (indicated by asterisks) have been omitted as the registrant has determined that the information is both not material and is the type that the registrant treats as private or confidential. ? ? ? ? ? ? ? IL-1 TARGET LICENSE AGREEMENT ? by and between XOMA (US) LLC and ? NOVARTIS PHARMA AG ? ? ? ? 276625499 v2 ? ? CONFIDENTIAL TABLE OF CONTENTS A

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): November 3, 2022 XOMA CORPORATION (Exact Name of Registrant as Specified in Charter) DELAWARE 001-39801 52-2154066 (State or Other Jurisdiction of Incorporation) (Commission File Numb

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): October 25, 2022 XOMA CORPORATION

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): October 25, 2022 XOMA CORPORATION (Exact Name of Registrant as Specified in Charter) DELAWARE 001-39801 52-2154066 (State or Other Jurisdiction of Incorporation) (Commission File Numb

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): September 28, 2022 XOMA CORPORATION (Exact Name of Registrant as Specified in Charter) DELAWARE 001-39801 52-2154066 (State or Other Jurisdiction of Incorporation) (Commission File Nu

XOMA Reports Second Quarter 2022 Financial Results and Highlights Recent Operational Events The completion of Regeneron’s acquisition of Checkmate Pharmaceuticals resulted in a $5 million milestone payment to Kuros, $2.5 million of which was paid to

Exhibit 99.1 XOMA Reports Second Quarter 2022 Financial Results and Highlights Recent Operational Events The completion of Regeneron?s acquisition of Checkmate Pharmaceuticals resulted in a $5 million milestone payment to Kuros, $2.5 million of which was paid to XOMA in July. Data from Rezolute and Day One led both companies to announce plans to move their assets into Phase 3 programs. Ended the s

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): August 4, 2022 XOMA CORPORATION (Exact Name of Registrant as Specified in Charter) DELAWARE 001-39801 52-2154066 (State or Other Jurisdiction of Incorporation) (Commission File Number

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) XOMA Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT THE SECURITIES ACT OF 1933 XOMA CORPORATION (Exact name of registrant as specified in its charter) Delaware 52-2154066 (State or other jurisdictio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 XOMA CORPORATION (Exact name of registrant as specified in its charter) Delaware 52-2154066 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification Number) 2200 Powell Street, Suite 310 Emeryville, California 94608 (Addresse

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): May 18, 2022 XOMA CORPORATION (Exact Name of Registrant as Specified in Charter) DELAWARE 001-39801 52-2154066 (State or Other Jurisdiction of Incorporation) (Commission File Number)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

The Retention and Severance Plan dated, March 31, 2022

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.

XOMA Reports First Quarter 2022 Financial Results and Highlights Recent Operational Events Earned a $2 million milestone from Rezolute as it dosed the final patient in a Phase 2 open-label study of RZ358 in patients with congenital hyperinsulinism in

Exhibit 99.1 XOMA Reports First Quarter 2022 Financial Results and Highlights Recent Operational Events Earned a $2 million milestone from Rezolute as it dosed the final patient in a Phase 2 open-label study of RZ358 in patients with congenital hyperinsulinism in early 2022. Rezolute has announced its intention to move RZ358 into Phase 3 clinical development. Roche?s novel bispecific antibody, in

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): May 5, 2022 XOMA CORPORATION (Exact Name of Registrant as Specified in Charter) DELAWARE 001-39801 52-2154066 (State or Other Jurisdiction of Incorporation) (Commission File Number) (

Letter Amendment to Officer Employment Agreement dated April 1, 2022, between the Company and Thomas Burns

Ex. 10.2 April 1, 2022 ? Thomas Burns VIA EMAIL/DOCUSIGN ? Dear Thomas: ? As you know, you are employed by XOMA Corporation (the ?Company?) pursuant to the terms of an Officer Employment Agreement (the ?Agreement?) dated August 7, 2017. You and the Company are hereby agreeing to amend the Agreement to include the retention benefit set forth below. ? In order to be eligible for the retention benefi

XOMA Corporation Amended and Restated 2010 Long Term Incentive and Stock Award Plan

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): March 31, 2022 XOMA CORPORATION (Exact Name of Registrant as Specified in Charter) DELAWARE 001-39801 52-2154066 (State or Other Jurisdiction of Incorporation) (Commission File Number

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Subsidiaries of the Company

? ? Exhibit 21.1 ? ? Subsidiaries of the Company Jurisdiction of Organization XOMA Technology Ltd. Bermuda XOMA (US) LLC Delaware XOMA UK Limited United Kingdom ?

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): March 8, 2022 XOMA CORPORATION (Exact Name of Registrant as Specified in Charter) DELAWARE 001-39801 52-2154066 (State or Other Jurisdiction of Incorporation) (Commission File Number)

XOMA Reports Full Year 2021 Financial Results and Highlights Recent Operational Events Earned $35 million milestone payment as NIS793 entered Phase 3 clinical study in metastatic pancreatic cancer Received $1.2 million from three milestone payments,

Exhibit 99.1 XOMA Reports Full Year 2021 Financial Results and Highlights Recent Operational Events Earned $35 million milestone payment as NIS793 entered Phase 3 clinical study in metastatic pancreatic cancer Received $1.2 million from three milestone payments, two of which were from a single Janssen asset and one was from Compugen Earned a $2 million milestone from Rezolute as it dosed the final

Description of Registrant’s Securities

Exhibit 4.6 DESCRIPTION OF XOMA CORPORATION CAPITAL STOCK The following is a description of the Common Stock, $0.0075 par value (the ?Common Stock?), Preferred Stock, $0.05 par value (the ?Preferred Stock?) and depositary shares of XOMA Corporation (the ?Company?). The Common Stock, 8.625% Series A Cumulative Perpetual Preferred Stock (the ?Series A Preferred Stock?) and the depositary shares (the

Commercial Payment Purchase Agreement, dated October 6, 2021, by and among XOMA (US) LLC and Affitech Research AS

EXECUTION COPY Exhibit 10.48 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential. ? ? ? ? ? ? ? COMMERCIAL PAYMENT PURCHASE AGREEMENT dated as of October 6, 2021 between Affitech Research AS, as Seller, and XOMA (US) LLC, as Purchaser ?

Amended and Restated Employment Agreement, dated December 15, 2021, between XOMA Corporation and James R. Neal

? Exhibit 10.26 AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Amended and Restated Employment Agreement (?Agreement?) between James R. Neal (?Employee?) and XOMA Corporation (?XOMA? or the ?Company?) (collectively, the ?Parties?) is effective as of December 15, 2021 (the ?Agreement Effective Date?). Preamble: ? XOMA wishes to enter into this Agreement to assure the continued services of Employee

XOMA / XOMA Corp / Eagle Point Credit Management LLC - SC 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* XOMA CORPORATION (Name of Issuer) Cumulative Perpetual Preferred Stock (Title of Class of Securities) 98419J404 (CUSIP Number(s)) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pu

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): January 28, 2022 XOMA CORPORATION (Exact Name of Registrant as Specified in Charter) DELAWARE 001-39801 52-2154066 (State or Other Jurisdiction of Incorporation) (Commission File Numb

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): December 15, 2021 XOMA CORPORATION (Exact Name of Registrant as Specified in Charter) DELAWARE 001-39801 52-2154066 (State or Other Jurisdiction of Incorporation) (Commission File Num

XOMA Reports Third Quarter 2021 Financial Results and Highlights Recent Operational Events Added eight assets to its portfolio of potential milestone and royalty assets in 2021 NIS793 in combination with standard of care chemotherapy was granted Orph

Exhibit 99.1 XOMA Reports Third Quarter 2021 Financial Results and Highlights Recent Operational Events Added eight assets to its portfolio of potential milestone and royalty assets in 2021 NIS793 in combination with standard of care chemotherapy was granted Orphan Drug Designation for the treatment of pancreatic cancer DAY101 received Rare Pediatric Disease Designation for the treatment of pediat

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): November 4, 2021 XOMA CORPORATION (Exact Name of Registrant as Specified in Charter) DELAWARE 001-39801 52-2154066 (State or Other Jurisdiction of Incorporation) (Commission File Numb

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): November 4, 2021 XOMA CORPORATION (Exact Name of Registrant as Specified in Charter) DELAWARE 001-39801 52-2154066 (State or Other Jurisdiction of Incorporation) (Commission File Numb

Royalty Purchase Agreement, dated July 14, 2021, by and among XOMA (US) LLC and Kuros Royalty Fund (US) LLC

Exhibit 10.2 ? [*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential. ? ?? ? ? ? ? ? ? ? ? ? ? ROYALTY PURCHASE AGREEMENT dated as of July 14, 2021 among KUROS BIOSCIENCES AG, as Swiss Parent KUROS US LLC, as US Parent KUROS ROYALTY FUND (

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 6, 2021 XOMA CORPORATION (Exact name of registrant as specified in its charter) 001-39801 Delaware 52-2154066 (Commission File Number) (State or other jurisd

Entry into a Material Definitive Agreement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): October 6, 2021 XOMA CORPORATION (Exact Name of Registrant as Specified in Charter) DELAWARE 001-39801 52-2154066 (State or Other Jurisdiction of Incorporation) (Commission File Numbe

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): August 27, 2021 XOMA CORPORATION (Exact Name of Registrant as Specified in Charter) DELAWARE 001-39801 52-2154066 (State or Other Jurisdiction of Incorporation) (Commission File Numbe

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 6, 2021 XOMA CORPORATION (Exact name of registrant as specified in its charter) 001-39801 Delaware 52-2154066 (Commission File Number) (State or other jurisdiction of incorporat

XOMA CORPORATION 2,000,000 Depositary Shares Each Representing 1/1000th of a Share of 8.375% Series B Cumulative Perpetual Preferred Stock (Liquidation Preference Equivalent to $25.00 Per Depositary Share)

Filed Pursuant to Rule 424(b)(5) Registration No. 333-254073 PROSPECTUS SUPPLEMENT (To Prospectus dated March 19, 2021) XOMA CORPORATION 2,000,000 Depositary Shares Each Representing 1/1000th of a Share of 8.375% Series B Cumulative Perpetual Preferred Stock (Liquidation Preference Equivalent to $25.00 Per Depositary Share) We have entered into an At Market Issuance Sales Agreement (the ?Sales Agr

Settlement and Release Agreement, dated April 15, 2021, by and among XOMA (US) LLC and Affimed N.V., Affimed GmbH Affimed

Exhibit 10.1 ? [*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential. ? MUTUAL CONFIDENTIAL SETTLEMENT AND RELEASE AGREEMENT This MUTUAL CONFIDENTIAL SETTLEMENT AND RELEASE AGREEMENT (?Release Agreement?) is made and entered into as of thi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Certificate of Amendment to the Certificate of Designation of 8.375% Series B Cumulative Perpetual Preferred Stock of XOMA Corporation.

Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE CERTIFICATE OF DESIGNATION OF 8.375% SERIES B CUMULATIVE PERPETUAL PREFERRED STOCK OF XOMA CORPORATION Pursuant to Section 151 of the General Corporation Law of the State of Delaware XOMA Corporation, a Delaware corporation (the ?Corporation?), does hereby certify as follows: FIRST: That the original Certificate of Designation of 8.375% Series B Cumulati

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): August 5, 2021 XOMA CORPORATION (Exact Name of Registrant as Specified in Charter) DELAWARE 001-39801 52-2154066 (State or Other Jurisdiction of Incorporation) (Commission File Number

Certificate of Correction of the Certificate of Designation of 8.375% Series B Cumulative Perpetual Preferred Stock

Exhibit 3.8 ? CERTIFICATE OF CORRECTION OF THE CERTIFICATE OF DESIGNATION OF 8.375% SERIES B CUMULATIVE PERPETUAL PREFERRED STOCK OF XOMA CORPORATION ? XOMA Corporation (the "Corpora?tion"), a corpora?tion orga?nized and existing under and by virtue of the Gener?al Corpo?ration Law of the State of Dela?ware, DOES HEREBY CERTIFY as follows: 1.The name of the corporation is XOMA Corporation. 2.The C

At Market Issuance Sales Agreement, dated August 5, 2021, by and between XOMA Corporation and B. Riley Securities, Inc.

Exhibit 10.1 XOMA CORPORATION Depositary Shares Each Representing 1/1000th of a Share of 8.375% Series B Cumulative Perpetual Preferred Stock At Market Issuance Sales Agreement August 5, 2021 B. Riley Securities, Inc. 299 Park Avenue, 21st Floor New York, NY 10171 Ladies and Gentlemen: XOMA Corporation, a Delaware corporation (the ?Company?), confirms its agreement (this ?Agreement?) with B. Riley

XOMA Reports Second Quarter 2021 Financial Results and Highlights Recent Operational Events Added six assets to its portfolio of potential milestone and royalty assets in 2021 Company earned $0.5 million milestone as Janssen asset entered Phase 3 dev

Exhibit 99.1 XOMA Reports Second Quarter 2021 Financial Results and Highlights Recent Operational Events Added six assets to its portfolio of potential milestone and royalty assets in 2021 Company earned $0.5 million milestone as Janssen asset entered Phase 3 development NIS793 in combination with standard of care chemotherapy was granted Orphan Drug Designation for the treatment pancreatic cancer

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): August 5, 2021 XOMA CORPORATION (Exact Name of Registrant as Specified in Charter) DELAWARE 001-39801 52-2154066 (State or Other Jurisdiction of Incorporation) (Commission File Number

Entry into a Material Definitive Agreement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): July 14, 2021 XOMA CORPORATION (Exact Name of Registrant as Specified in Charter) DELAWARE 001-39801 52-2154066 (State or Other Jurisdiction of Incorporation) (Commission File Number)

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): May 19, 2021 XOMA CORPORATION (Exact Name of Registrant as Specified in Charter) DELAWARE 001-39801 52-2154066 (State or Other Jurisdiction of Incorporation) (Commission File Number)

Quarterly Report - 10-Q

Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.